268 related articles for article (PubMed ID: 28671000)
21. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
22. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial.
Jena M; Ranjan R; Mishra BR; Mishra A; Nath S; Sahu P; Meher BR; Srinivasan A; Maiti R
J Psychiatr Res; 2019 May; 112():1-6. PubMed ID: 30782512
[TBL] [Abstract][Full Text] [Related]
23. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.
Citrome L; Casey DE; Daniel DG; Wozniak P; Kochan LD; Tracy KA
Psychiatr Serv; 2004 Mar; 55(3):290-4. PubMed ID: 15001730
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
Kinon BJ; Liu-Seifert H; Ahl J; Ahmed S; Baker RW
Ann N Y Acad Sci; 2004 Dec; 1032():295-6. PubMed ID: 15677433
[TBL] [Abstract][Full Text] [Related]
25. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy.
Hori H; Yoshimura R; Katsuki A; Atake K; Igata R; Konishi Y; Nakamura J
World J Biol Psychiatry; 2017 Aug; 18(5):401-408. PubMed ID: 27409727
[TBL] [Abstract][Full Text] [Related]
26. Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia.
Li J; Ye F; Xiao W; Tang X; Sha W; Zhang X; Wang J
Eur Psychiatry; 2016 Aug; 36():23-8. PubMed ID: 27311104
[TBL] [Abstract][Full Text] [Related]
27. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
Casey DE; Daniel DG; Tamminga C; Kane JM; Tran-Johnson T; Wozniak P; Abi-Saab W; Baker J; Redden L; Greco N; Saltarelli M
Neuropsychopharmacology; 2009 Apr; 34(5):1330-8. PubMed ID: 19052541
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
29. [Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia].
Zhao J; Zhang Y; Chao YY; Ma J; Yang YF; Zhao JY; Du YH; Li WW; Song XQ; Lü LX
Zhonghua Yi Xue Za Zhi; 2016 Oct; 96(37):2960-2964. PubMed ID: 27760654
[No Abstract] [Full Text] [Related]
30. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
Misiak B; Frydecka D; Łaczmański Ł; Ślęzak R; Kiejna A
Eur J Clin Pharmacol; 2014 Dec; 70(12):1433-41. PubMed ID: 25291992
[TBL] [Abstract][Full Text] [Related]
31. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
32. Risperidone-related weight gain: genetic and nongenetic predictors.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
[TBL] [Abstract][Full Text] [Related]
33. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
34. [Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia].
Govorin NV; Vasil'eva AI
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(3):54-7. PubMed ID: 21423116
[TBL] [Abstract][Full Text] [Related]
35. Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics.
Bas A; Gultekin G; Incir S; Bas TO; Emul M; Duran A
Psychiatry Res; 2017 Jan; 247():84-89. PubMed ID: 27871032
[TBL] [Abstract][Full Text] [Related]
36. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.
Hatta K; Otachi T; Sudo Y; Hayakawa T; Ashizawa Y; Takebayashi H; Hayashi N; Hamakawa H; Ito S; Nakase R; Usui C; Nakamura H; Hirata T; Sawa Y;
Schizophr Res; 2011 May; 128(1-3):127-35. PubMed ID: 21420283
[TBL] [Abstract][Full Text] [Related]
37. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine.
Yamamori H; Hashimoto R; Ishima T; Kishi F; Yasuda Y; Ohi K; Fujimoto M; Umeda-Yano S; Ito A; Hashimoto K; Takeda M
Neurosci Lett; 2013 Nov; 556():37-41. PubMed ID: 24141084
[TBL] [Abstract][Full Text] [Related]
38. Superoxide Dismutase, BDNF, and Cognitive Improvement in Drug-Naive First-Episode Patients With Schizophrenia: A 12-Week Longitudinal Study.
Wu Z; Liu Q; Zhang Y; Guan X; Xiu M; Zhang X
Int J Neuropsychopharmacol; 2022 Feb; 25(2):128-135. PubMed ID: 34622272
[TBL] [Abstract][Full Text] [Related]
39. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics.
Zhang XY; Tan YL; Zhou DF; Cao LY; Wu GY; Xu Q; Shen Y; Haile CN; Kosten TA; Kosten TR
J Psychiatr Res; 2007 Dec; 41(12):997-1004. PubMed ID: 17095017
[TBL] [Abstract][Full Text] [Related]
40. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Heresco-Levy U; Javitt DC; Ebstein R; Vass A; Lichtenberg P; Bar G; Catinari S; Ermilov M
Biol Psychiatry; 2005 Mar; 57(6):577-85. PubMed ID: 15780844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
